LenioBio GmbH

LenioBio GmbH is a biotechnology company that has developed a proprietary, cell-free protein expression platform known as ALiCE. Headquartered in Düsseldorf, Germany, the company provides this technology to enable the rapid discovery, development, and scalable production of complex proteins, including antibodies, enzymes, and viral antigens. Unlike traditional cell-based methods that can be limited by toxicity or slow growth, the ALiCE platform utilizes a plant-based, eukaryotic cell-free system that contains active microsomes for complex post-translational modifications, such as disulfide bonding and N-glycosylation. This technology allows for the production of proteins that are otherwise difficult to express, potentially reducing manufacturing bottlenecks and production times from months to days.

By offering a scalable solution that works from microlitre to industrial scales, LenioBio addresses critical challenges in the biopharmaceutical industry, particularly the need for faster, more cost-effective protein manufacturing. The company's technology supports researchers and manufacturers throughout the drug discovery and development lifecycle, from lead identification and pre-clinical analysis to large-scale production. LenioBio collaborates with various industry partners to accelerate the development of protein therapeutics and vaccines, aiming to make advanced medicine production more accessible and efficient. The company is currently working toward GMP certification to further support clinical-stage manufacturing and large-scale commercial production.